PDF herunterladen
Am J Perinatol 2024; 41(S 01): e2521-e2528
DOI: 10.1055/s-0043-1771504
Original Article

Ureaplasma and Mycoplasma Screening for Pregnant Individuals Who Are at High Risk for Preterm Birth

Tetsuya Kawakita
1   Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, Virginia
,
Jerri Waller
1   Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, Virginia
,
Tracey DeYoung
1   Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, Virginia
,
Lea Nehme
1   Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, Virginia
,
Madison C. Collazo
2   Department of Obstetrics and Gynecology, Inova Fairfax Hospital, Falls Church, Virginia
,
Carole Barake
3   Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, Texas
,
Monica A. Ethirajan
1   Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, Virginia
,
Camille M. Kanaan
1   Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, Virginia
,
Alfred Abuhamad
1   Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, Virginia
› Institutsangaben Funding None.
› Weitere Informationen
Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Objective This study aimed to examine gestational age at delivery according to Ureaplasma/Mycoplasma cervical culture results and whether pregnant individuals received antibiotics.

Study Design A retrospective cohort study at a single academic institution where all pregnant individuals with risk factors for preterm birth including those with a history of preterm birth, recurrent pregnancy loss, or pregnancy requiring cervical cerclage were included. We plotted Kaplan–Meier curves to investigate the association between the gestational age at delivery and Ureaplasma culture results (negative; positive and treated; or positive but did not receive the treatment). A Cox proportional regression model was used to calculate hazard ratio (HR) with 95% confidence intervals (95% CI), controlling for confounders. The main outcome was age at delivery. Analyses were repeated for Mycoplasma culture.

Results Of 607 individuals, 258 (42.5%) had a negative Ureaplasma culture, 308 (50.7%) had a positive Ureaplasma culture and received treatment, and 41 (6.8%) had a positive Ureaplasma culture and did not receive treatment. Compared with those who had a positive Ureaplasma culture but did not receive treatment, those who had a negative Ureaplasma culture did not have a decreased risk (HR: 1.03; 95% CI: 0.74–1.44). Compared with those who had a positive Ureaplasma culture but did not receive treatment, those who had a positive Ureaplasma culture and received treatment did not have a decreased risk (HR: 0.91; 95% CI: 0.66–1.27). The treatment failure rate of Ureaplasma after treatment was 78.6% (95% CI: 72.8–83.7%). Overall, the findings of Mycoplasma were similar.

Conclusion Routine ureaplasma/mycoplasma cervical culture is not recommended for pregnant individuals who are at high risk for preterm birth.

Key Points

  • Ureaplasma/mycoplasma species are isolated in patients with preterm birth.

  • High ureaplasma/mycoplasma recurrence rate despite treatment with antibiotics.

  • Treatment of patient and partner did not improve gestational age at delivery.

Keywords

antibiotics - mycoplasma - preterm birth - quality initiative - recurrence - ureaplasma

Ethical Approval

This study was approved by the Eastern Virginia Medical School Institutional Review Board (IRB approval no.: 21-02-XX-0032) On April 30, 2021.


Supplementary Material



Publikationsverlauf

Eingereicht: 07. Januar 2023

Angenommen: 30. Juni 2023

Artikel online veröffentlicht:
29. Juli 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Martin JA, Osterman MJK, Sutton PD. Are preterm births on the decline in the United States? Recent data from the National Vital Statistics System. NCHS Data Brief 2010; (39) 1-8
    PubMedSuche in Google Scholar
  • 2 Blencowe H, Cousens S. Addressing the challenge of neonatal mortality. Trop Med Int Health 2013; 18 (03) 303-312
    CrossrefPubMedSuche in Google Scholar
  • 3 Paneth NS. The problem of low birth weight. Future Child 1995; 5 (01) 19-34
    CrossrefPubMedSuche in Google Scholar
  • 4 Edlow AG, Srinivas SK, Elovitz MA. Second-trimester loss and subsequent pregnancy outcomes: what is the real risk?. Am J Obstet Gynecol 2007; 197 (06) 581.e1-581.e6
    CrossrefPubMedSuche in Google Scholar
  • 5 Sprong KE, Mabenge M, Wright CA, Govender S. Ureaplasma species and preterm birth: current perspectives. Crit Rev Microbiol 2020; 46 (02) 169-181
    CrossrefPubMedSuche in Google Scholar
  • 6 Andrews WW, Goldenberg RL, Mercer B. et al. The preterm prediction study: association of second-trimester genitourinary chlamydia infection with subsequent spontaneous preterm birth. Am J Obstet Gynecol 2000; 183 (03) 662-668
    CrossrefPubMedSuche in Google Scholar
  • 7 Meis PJ, Goldenberg RL, Mercer B. et al; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. The preterm prediction study: significance of vaginal infections. Am J Obstet Gynecol 1995; 173 (04) 1231-1235
    CrossrefPubMedSuche in Google Scholar
  • 8 Van Gerwen OT, Craig-Kuhn MC, Jones AT. et al. Trichomoniasis and adverse birth outcomes: a systematic review and meta-analysis. BJOG 2021; 128 (12) 1907-1915
    CrossrefPubMedSuche in Google Scholar
  • 9 Sweeney EL, Kallapur SG, Gisslen T. et al. Placental infection with ureaplasma species is associated with histologic chorioamnionitis and adverse outcomes in moderately preterm and late-preterm infants. J Infect Dis 2016; 213 (08) 1340-1347
    CrossrefPubMedSuche in Google Scholar
  • 10 Romero R, Mazor M, Oyarzun E, Sirtori M, Wu YK, Hobbins JC. Is genital colonization with Mycoplasma hominis or Ureaplasma urealyticum associated with prematurity/low birth weight?. Obstet Gynecol 1989; 73 (3 Pt 2): 532-536
    PubMedSuche in Google Scholar
  • 11 Kacerovsky M, Kukla R, Bolehovska R. et al. Prevalence and load of cervical ureaplasma species with respect to intra-amniotic complications in women with preterm prelabor rupture of membranes before 34 weeks. Front Pharmacol 2022; 13: 860498
    CrossrefPubMedSuche in Google Scholar
  • 12 Rittenschober-Böhm J, Waldhoer T, Schulz SM. et al. Vaginal Ureaplasma parvum serovars and spontaneous preterm birth. Am J Obstet Gynecol 2019; 220 (06) 594.e1-594.e9
    CrossrefPubMedSuche in Google Scholar
  • 13 Payne MS, Ireland DJ, Watts R. et al. Ureaplasma parvum genotype, combined vaginal colonisation with Candida albicans, and spontaneous preterm birth in an Australian cohort of pregnant women. BMC Pregnancy Childbirth 2016; 16 (01) 312-x
    CrossrefPubMedSuche in Google Scholar
  • 14 Pararas MV, Skevaki CL, Kafetzis DA. Preterm birth due to maternal infection: causative pathogens and modes of prevention. Eur J Clin Microbiol Infect Dis 2006; 25 (09) 562-569
    CrossrefPubMedSuche in Google Scholar
  • 15 Eschenbach DA, Nugent RP, Rao AV. et al; The Vaginal Infections and Prematurity Study Group. A randomized placebo-controlled trial of erythromycin for the treatment of Ureaplasma urealyticum to prevent premature delivery. Am J Obstet Gynecol 1991; 164 (03) 734-742
    CrossrefPubMedSuche in Google Scholar
  • 16 Raynes Greenow CH, Roberts CL, Bell JC, Peat B, Gilbert GL, Parker S. Antibiotics for Ureaplasma in the vagina in pregnancy. Cochrane Database Syst Rev 2011; 2011 (09) CD003767
    PubMedSuche in Google Scholar
  • 17 Oh KJ, Romero R, Park JY. et al. Evidence that antibiotic administration is effective in the treatment of a subset of patients with intra-amniotic infection/inflammation presenting with cervical insufficiency. Am J Obstet Gynecol 2019; 221 (02) 140.e1-140.e18
    CrossrefPubMedSuche in Google Scholar
  • 18 Ogasawara KK, Goodwin TM. Efficacy of azithromycin in reducing lower genital Ureaplasma urealyticum colonization in women at risk for preterm delivery. J Matern Fetal Med 1999; 8 (01) 12-16
    CrossrefPubMedSuche in Google Scholar
  • 19 Prediction and Prevention of Spontaneous Preterm Birth. Prediction and prevention of spontaneous preterm birth: ACOG practice bulletin, number 234. Obstet Gynecol 2021; 138 (02) e65-e90
    CrossrefPubMedSuche in Google Scholar
  • 20 Prelabor Rupture of Membranes. Prelabor rupture of membranes: ACOG practice bulletin, number 217. Obstet Gynecol 2020; 135 (03) e80-e97
    CrossrefPubMedSuche in Google Scholar
  • 21 Practice Committee of American Society for Reproductive Medicine. Definitions of infertility and recurrent pregnancy loss: a committee opinion. Fertil Steril 2013; 99 (01) 63
    CrossrefPubMedSuche in Google Scholar
  • 22 American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. ACOG practice bulletin no.142: cerclage for the management of cervical insufficiency. Obstet Gynecol 2014; 123 (2 Pt 1): 372-379
    CrossrefPubMedSuche in Google Scholar
  • 23 Committee opinion no 700: methods for estimating the due date. Obstet Gynecol 2017; 129 (05) e150-e154
    CrossrefPubMedSuche in Google Scholar
  • 24 Yoon BH, Romero R, Park JY. et al. Antibiotic administration can eradicate intra-amniotic infection or intra-amniotic inflammation in a subset of patients with preterm labor and intact membranes. Am J Obstet Gynecol 2019; 221 (02) 142.e1-142.e22
    CrossrefPubMedSuche in Google Scholar
  • 25 Schneider SC, Tinguely R, Droz S. et al. Antibiotic susceptibility and sequence type distribution of Ureaplasma species isolated from genital samples in Switzerland. Antimicrob Agents Chemother 2015; 59 (10) 6026-6031
    CrossrefPubMedSuche in Google Scholar
  • 26 Klein LL, Gibbs RS. Use of microbial cultures and antibiotics in the prevention of infection-associated preterm birth. Am J Obstet Gynecol 2004; 190 (06) 1493-1502
    CrossrefPubMedSuche in Google Scholar
  • 27 Tantengco OAG, Yanagihara I. Current understanding and treatment of intra-amniotic infection with Ureaplasma spp. J Obstet Gynaecol Res 2019; 45 (09) 1796-1808
    CrossrefPubMedSuche in Google Scholar
  • 28 Tita AT, Szychowski JM, Boggess K. et al; C/SOAP Trial Consortium. Adjunctive azithromycin prophylaxis for cesarean delivery. N Engl J Med 2016; 375 (13) 1231-1241
    CrossrefPubMedSuche in Google Scholar
  • 29 Azad MB, Konya T, Persaud RR. et al; CHILD Study Investigators. Impact of maternal intrapartum antibiotics, method of birth and breastfeeding on gut microbiota during the first year of life: a prospective cohort study. BJOG 2016; 123 (06) 983-993
    CrossrefPubMedSuche in Google Scholar
  • 30 Motomura K, Romero R, Xu Y. et al. Intra-amniotic infection with Ureaplasma parvum causes preterm birth and neonatal mortality that are prevented by treatment with clarithromycin. MBio 2020; 11 (03) e00797-e20
    CrossrefPubMedSuche in Google Scholar